UroToday

WSAUA 2025: Long-Term Outcomes of Primary Chemoablation of New-Onset or Recurrent Low Grade Upper Tract Urothelial Carcinoma with UGN-101, a Mitomycin …

Patients with low-grade upper tract urothelial carcinoma who achieved a complete response after receiving treatment with ...
UroToday

WSAUA 2025: Comparative Performance of UNFOLD AI, PSMA-PET, and mpMRI for Prostate Cancer Localization and Pathologic Staging

Dr. Lee concluded his presentation discussing the comparative performance of UNFOLD AI, PSMA-PET, and mpMRI for prostate ...
UroToday

WSAUA 2025: Impact of Neoadjuvant Systemic Therapy on Tumor and Tumor Thrombus Regression in Renal Cell Carcinoma with Venous Involvement: A Retrospective Analysis

The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...
UroToday

WSAUA 2025: Impact of Bone Protecting Agents on Outcomes with Enzalutamide, with or without Radium-223, in Asymptomatic/mildly Symptomatic Patients with Bone mCRPC from PEACE-3

Patients with bone-protecting agent use versus no bone-protecting agent had similar baseline characteristics: ...
UroToday

Study on Metastatic Hormone-Sensitive Prostate Cancer Survival Trends - Neeraj Agarwal

Neeraj Agarwal discusses a Flatiron database analysis examining treatment intensification in metastatic hormone-sensitive prostate cancer. The study analyzed approximately 10,000 patients treated ...
UroToday

LUGPA 2025 Annual Meeting

Were you unable to attend LUGPA 2025 Annual Meeting? Get all of the groundbreaking research, new guidelines, ...